Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vieworks Co., Ltd. (100120.KQ)
Anyang-Si, KR
Vieworks Co., Ltd. is dedicated to the development, manufacturing, and sale of comprehensive imaging systems and solutions. The company provides X-ray detectors alongside image processing technologies utilized across numerous fields, including general and veterinary radiography systems, dental and surgical C-arm systems, radiography and fluoroscopy setups, and industrial inspection instruments. Beyond its X-ray offerings, Vieworks also produces industrial-grade cameras and specialized bio-imaging systems, which encompass in vivo imaging solutions under the VISQUE brand. Founded in 1999, the organization was formerly known as Raysis Co., Ltd. before officially changing its name to Vieworks Co., Ltd. in November 2006. The company maintains its headquarters in Anyang-si, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.36% | +12.79% | +32.82% | +29.81% | +78.05% | +74.71% | +39.55% | +2.99% | -9.35% | -32.15% | +149.27% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+7.4% Q1'26: +6.9% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+4.9% Q1'26: +317.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+4.1% Q1'26: +8.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.9% ★ Q1'26: +15.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+6.7% ★ Q1'26: +11.6% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+1.9% Q1'26: -4.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.36× Q1'26: 1.98× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
93.44B
est: 90.85B (+2.9%)
|
117.30B
est: 116.72B (+0.5%)
|
123.46B
est: 123.00B (+0.4%)
|
131.40B
est: 131.01B (+0.3%)
|
136.01B
est: 136.00B (+0.0%)
|
160.26B
est: 160.00B (+0.2%)
|
193.14B
est: 193.05B (+0.0%)
|
237.93B
est: 237.95B (0.0%)
|
220.25B
est: 219.77B (+0.2%)
|
222.90B
est: 225.13B (-1.0%)
|
239.34B
est: 235.45B (+1.7%)
|
258.27B
252.90B – 264.24B
+9.7% YoY
|
281.33B
274.34B – 293.38B
+8.9% YoY
|
290.30B
283.65B – 299.99B
+3.2% YoY
|
| EBITDA |
22.78B
est: 16.04B (+42.0%)
|
36.84B
est: 20.61B (+78.8%)
|
26.98B
est: 21.72B (+24.2%)
|
28.31B
est: 23.13B (+22.4%)
|
33.69B
est: 24.02B (+40.3%)
|
31.84B
est: 28.25B (+12.7%)
|
45.56B
est: 34.09B (+33.7%)
|
40.66B
est: 42.02B (-3.2%)
|
26.16B
est: 38.81B (-32.6%)
|
35.37B
est: 36.39B (-2.8%)
|
29.66B
est: 38.06B (-22.1%)
|
41.74B
40.88B – 42.71B
+9.7% YoY
|
45.47B
44.34B – 47.42B
+8.9% YoY
|
46.92B
45.85B – 48.49B
+3.2% YoY
|
| EBIT |
19.16B
est: 13.43B (+42.6%)
|
33.38B
est: 17.26B (+93.4%)
|
23.26B
est: 18.19B (+27.8%)
|
25.20B
est: 19.37B (+30.1%)
|
30.23B
est: 20.11B (+50.3%)
|
28.02B
est: 23.66B (+18.4%)
|
40.00B
est: 28.55B (+40.1%)
|
34.54B
est: 35.19B (-1.8%)
|
19.17B
est: 32.50B (-41.0%)
|
27.93B
est: 29.44B (-5.1%)
|
21.19B
est: 30.79B (-31.2%)
|
33.78B
33.07B – 34.56B
+9.7% YoY
|
36.79B
35.88B – 38.37B
+8.9% YoY
|
37.97B
37.10B – 39.23B
+3.2% YoY
|
| Net Income |
15.90B
est: 14.99B (+6.1%)
|
26.98B
est: 23.24B (+16.1%)
|
19.63B
est: 20.52B (-4.3%)
|
20.77B
est: 18.78B (+10.6%)
|
24.22B
est: 24.75B (-2.1%)
|
22.89B
est: 21.06B (+8.7%)
|
33.47B
est: 31.82B (+5.2%)
|
26.54B
est: 25.39B (+4.5%)
|
14.71B
est: 14.59B (+0.8%)
|
21.30B
est: 18.97B (+12.3%)
|
21.97B
est: 15.48B (+41.9%)
|
31.62B
29.53B – 33.38B
+104.2% YoY
|
35.65B
32.47B – 38.22B
+12.7% YoY
|
38.25B
37.12B – 39.91B
+7.3% YoY
|
| SGA |
6.12B
est: 7.00B (-12.5%)
|
6.52B
est: 8.99B (-27.5%)
|
7.05B
est: 9.48B (-25.6%)
|
10.80B
est: 10.09B (+7.0%)
|
12.21B
est: 10.48B (+16.5%)
|
11.66B
est: 12.33B (-5.4%)
|
13.60B
est: 14.87B (-8.6%)
|
16.57B
est: 18.33B (-9.6%)
|
18.11B
est: 16.93B (+6.9%)
|
20.11B
est: 18.07B (+11.3%)
|
21.28B
est: 18.90B (+12.6%)
|
20.73B
20.30B – 21.21B
+9.7% YoY
|
22.58B
22.02B – 23.55B
+8.9% YoY
|
23.30B
22.77B – 24.08B
+3.2% YoY
|
| EPS |
1,589.49
est: 1,632.28 (-2.6%)
|
2,701.27
est: 2,531.02 (+6.7%)
|
1,971.00
est: 2,234.47 (-11.8%)
|
2,095.29
est: 2,045.06 (+2.5%)
|
2,457.26
est: 2,695.00 (-8.8%)
|
2,394.56
est: 2,294.00 (+4.4%)
|
3,575.35
est: 3,465.50 (+3.2%)
|
2,890.32
est: 2,765.50 (+4.5%)
|
1,602.58
est: 1,589.33 (+0.8%)
|
2,317.24
est: 2,026.25 (+14.4%)
|
2,433.75
est: 1,654.00 (+47.1%)
|
3,378.00
3,154.59 – 3,566.22
+104.2% YoY
|
3,808.67
3,469.18 – 4,083.86
+12.7% YoY
|
4,087.00
3,965.35 – 4,264.31
+7.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Choul-Woo Park | Chief of Industrial Device Development Unit & Director | — | male |
| Hooshik Kim | Chief Executive Officer | — | male |
| Hyung-Tae Kim | Quality Assurance Team Manager & Director | — | male |
| Im Jae-Hee | Chief of Medical Device Development Unit & Director | — | male |
| Jang Hyeon-Seok | Chief of New Business Development Unit & Director | — | male |
| Kwang-Yong Hong | Sales Team Manager & Director | — | male |
| Kyung-Ryoul Seo | Senior MD, Director of Research Center, GM of Sales & Director | — | male |
| Young-ki Seo | Head of Management Support Division & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 100120.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
